Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Associate

Kimberly Larie

Goodwin Procter

main

Larie Kimberly

Goodwin Associate Kimberly Larie, from Boston, practices in the firm's Business Law Department. Learn more about Kimberly's experience and contact details.

Kimberly Larie

Areas of Practice

Credentials

Education

JD2017

M.A. in Secondary EducationMathematics2014

BA, EconomicsMathematics2012

Admissions

Bars

Related Content

What’s in a Name? Why Your “Dual Class” IPO Should Be a “Dual Series” IPO Instead

Wayfair Closes $690 Million Convertible Notes Offering with Capped Call

Klaviyo and Shopify Announce Strategic Partnership

Frazier Healthcare Partners Acquires Apollo Intelligence

Bright Health Completes $924.3 Million Initial Public Offering

Klaviyo Raises $320 Million in Series D Funding

Capital Markets Team Advises Underwriters of $128.2 Million Opthea Initial Public Offering

Kabbage to Join American Express

Corvidia Therapeutics to be Acquired by Novo Nordisk for $725 Million Upfront and up to $2.1 Billion in Total

Technology M&A